Ghada Nabil Elnaggar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ghada Nabil Elnaggar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Abeer Ismail
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
2 shared publicationsAbbas Mohamed
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publicationAhmad Samir Elshazly
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publicationDina M. Elkhashab
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publicationLamiaa Ali Bayoumi
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publicationMaha Yahia
Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (7) , 2479-2487
Role of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers, and the second cause of cancer-related deaths worldwide. MicroRNAs play a role in regulating gene expression transcriptionally and post-transcriptionally. Accordingly, they can affect cancer risk. This study aimed to highlight the diagnostic role of miR-15b and miR-130b as non-invasive biomarkers in Egyptian HCC patients. Materials and Methods: This study included 70 patients with confirmed HCC, 35 cirrhotic patients with chronic hepatitis B or C virus infection, and 35 apparently healthy persons. Plasma miR-15b and miR-130b levels were measured by TaqMan RT-PCR assay. Results: Significant higher expression levels of plasma miR-15b and miR-130b were observed in HCC patients compared to hepatitis group or control group or the non-malignant group (P <0.0001 each). Combining miR-15b with AFP markedly raised the sensitivity to 91.4%, while combination of miR-130b with AFP significantly improved the specificity to 97.1 %. Combining the three markers showed excellent discriminatory power with AUC 0.959 and overall diagnostic accuracy 92.6% for differentiation between HCC from the non-malignant cases. Conclusion: MiR-15b and miR-130b could serve as possible biomarkers for HCC detection, and combining these markers with AFP could markedly improve the diagnostic accuracy for HCC.
- 1 July 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (7) , 2479-2487
Open AccessRole of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers, and the second cause of cancer-related deaths worldwide. MicroRNAs play a role in regulating gene expression transcriptionally and post-transcriptionally. Accordingly, they can affect cancer risk. This study aimed to highlight the diagnostic role of miR-15b and miR-130b as non-invasive biomarkers in Egyptian HCC patients. Materials and Methods: This study included 70 patients with confirmed HCC, 35 cirrhotic patients with chronic hepatitis B or C virus infection, and 35 apparently healthy persons. Plasma miR-15b and miR-130b levels were measured by TaqMan RT-PCR assay. Results: Significant higher expression levels of plasma miR-15b and miR-130b were observed in HCC patients compared to hepatitis group or control group or the non-malignant group (P <0.0001 each). Combining miR-15b with AFP markedly raised the sensitivity to 91.4%, while combination of miR-130b with AFP significantly improved the specificity to 97.1 %. Combining the three markers showed excellent discriminatory power with AUC 0.959 and overall diagnostic accuracy 92.6% for differentiation between HCC from the non-malignant cases. Conclusion: MiR-15b and miR-130b could serve as possible biomarkers for HCC detection, and combining these markers with AFP could markedly improve the diagnostic accuracy for HCC.
- Open Access
- 1 September 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (9) , 3269-3274
Possible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma
Objective: Osteosarcoma is considered the most common primary malignant tumor that develops from the primary osteoblasts. MiRNAs are small non-coding RNAs that play a key role in tumorigenesis. The aim of this study was to detect the possible relationship between expression levels of miRNA-34a and levels of Signal transducer and activator of transcription 3 (STAT3) and interleukin-6 receptor (IL-6R) in osteosarcoma and the possible role of this relationship in development of metastases in these patients. Methods: A total of thirty-six (36) bone samples were included in the study. They were divided into 3 groups: Group (I): Twelve normal bone samples as control group. Group (II): Twelve patients with non-metastatic osteosarcoma. Group (III): Twelve patients with metastatic osteosarcoma. MiRNA-34a expression levels were estimated using qRT-PCR. STAT3 and IL-6R levels were measured by ELISA. Results: Expression level of miRNA-34a was downregulated in osteosarcoma groups compared to control group. STAT3 and IL-6R levels were upregulated in osteosarcoma groups compared to control group. This difference in expression levels was found to be more significant in the metastatic group than the non-metastatic one (P<0.001 each). There was a significant positive correlation between STAT3 and IL-6R (r=0.868, P<0.001), and a significant inverse correlation between IL6 and miRNA-34a (r=-0.993, P<0.001). Conclusion: miRNA-34a, STAT3 and IL-6R feedback loop could be a potential target for treatment of osteosarcoma and can be used as prognostic indicator for this disease.
- 1 September 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (9) , 3269-3274
Open AccessPossible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma
Objective: Osteosarcoma is considered the most common primary malignant tumor that develops from the primary osteoblasts. MiRNAs are small non-coding RNAs that play a key role in tumorigenesis. The aim of this study was to detect the possible relationship between expression levels of miRNA-34a and levels of Signal transducer and activator of transcription 3 (STAT3) and interleukin-6 receptor (IL-6R) in osteosarcoma and the possible role of this relationship in development of metastases in these patients. Methods: A total of thirty-six (36) bone samples were included in the study. They were divided into 3 groups: Group (I): Twelve normal bone samples as control group. Group (II): Twelve patients with non-metastatic osteosarcoma. Group (III): Twelve patients with metastatic osteosarcoma. MiRNA-34a expression levels were estimated using qRT-PCR. STAT3 and IL-6R levels were measured by ELISA. Results: Expression level of miRNA-34a was downregulated in osteosarcoma groups compared to control group. STAT3 and IL-6R levels were upregulated in osteosarcoma groups compared to control group. This difference in expression levels was found to be more significant in the metastatic group than the non-metastatic one (P<0.001 each). There was a significant positive correlation between STAT3 and IL-6R (r=0.868, P<0.001), and a significant inverse correlation between IL6 and miRNA-34a (r=-0.993, P<0.001). Conclusion: miRNA-34a, STAT3 and IL-6R feedback loop could be a potential target for treatment of osteosarcoma and can be used as prognostic indicator for this disease.
- Open Access
- 1 June 2021
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 22 (6) , 1949-1955
Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer
Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins. Materials and Methods: A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA. Results: Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p
- 1 June 2021
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 22 (6) , 1949-1955
Open AccessMicro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer
Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins. Materials and Methods: A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA. Results: Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p